Type I IFNs Promote Cancer Cell Stemness by Triggering the Epigenetic Regulator KDM1B

Cancer stem cells (CSCs) are a subpopulation of cancer cells endowed with high tumorigenic, chemoresistant and metastatic potential. Nongenetic mechanisms of acquired resistance are increasingly being discovered, but molecular insights into the evolutionary process of CSCs are limited. Here, we show that type I interferons (IFNs-I) function as molecular hubs of resistance during immunogenic chemotherapy, triggering the epigenetic regulator demethylase 1B (KDM1B) to promote an adaptive, yet reversible, transcriptional rewiring of cancer cells towards stemness and immune escape. Accordingly, KDM1B inhibition prevents the appearance of IFN-I-induced CSCs, both in vitro and in vivo. Notably, IFN-I-induced CSCs are heterogeneous in terms of multidrug resistance, plasticity, invasiveness and immunogenicity. Moreover, in breast cancer (BC) patients receiving anthracycline-based chemotherapy, KDM1B positively correlated with CSC signatures. Our study identifies an IFN-I → KDM1B axis as a potent engine of cancer cell reprogramming, supporting KDM1B targeting as an attractive adjunctive to immunogenic drugs to prevent CSC expansion and increase the long-term benefit of therapy.

Citing Articles

Transcriptomic profiling reveals mechanism, therapeutic potential, and prognostic value of cancer stemness characteristic in nasopharyngeal carcinoma.

Chen J, Shen R, Zhu J, Wang Y, Fu L, Chen Y Funct Integr Genomics. 2025; 25(1):56.

PMID: 40053129 DOI: 10.1007/s10142-025-01561-w.

Cancer stem cells and niches: challenges in immunotherapy resistance.

Pan Y, Yuan C, Zeng C, Sun C, Xia L, Wang G Mol Cancer. 2025; 24(1):52.

PMID: 39994696 PMC: 11852583. DOI: 10.1186/s12943-025-02265-2.

Intestinal stem cells in intestinal homeostasis and colorectal tumorigenesis.

Shi G, Li Y, Shen H, He Q, Zhu P Life Med. 2025; 3(5):lnae042.

PMID: 39872442 PMC: 11749485. DOI: 10.1093/lifemedi/lnae042.

Everything you ever wanted to know about cancer stem cells in neuroendocrine neoplasms but were afraid to ask.

Ruz-Caracuel I, Pedraza-Arevalo S, Alonso-Gordoa T, Molina-Cerrillo J, Earl J, Sainz Jr B Endocr Oncol. 2025; 4(1):e240006.

PMID: 39822777 PMC: 11737516. DOI: 10.1530/EO-24-0006.

Identification of a distinctive immunogenomic gene signature in stage-matched colorectal cancer.

Ahluwalia P, Mondal A, Vashisht A, Singh H, Alptekin A, Ballur K J Cancer Res Clin Oncol. 2024; 151(1):9.

PMID: 39673574 PMC: 11646222. DOI: 10.1007/s00432-024-06034-4.

References

Wu X, Dao Thi V, Huang Y, Billerbeck E, Saha D, Hoffmann H . Intrinsic Immunity Shapes Viral Resistance of Stem Cells. Cell. 2017; 172(3):423-438.e25. PMC: 5786493. DOI: 10.1016/j.cell.2017.11.018. View

Hollern D, Xu N, Thennavan A, Glodowski C, Garcia-Recio S, Mott K . B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer. Cell. 2019; 179(5):1191-1206.e21. PMC: 6911685. DOI: 10.1016/j.cell.2019.10.028. View

Al-Hajj M, Wicha M, Benito-Hernandez A, Morrison S, Clarke M . Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003; 100(7):3983-8. PMC: 153034. DOI: 10.1073/pnas.0530291100. View

Weichselbaum R, Ishwaran H, Yoon T, Nuyten D, Baker S, Khodarev N . An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci U S A. 2008; 105(47):18490-5. PMC: 2587578. DOI: 10.1073/pnas.0809242105. View

Lee J, Sayed N, Hunter A, Au K, Wong W, Mocarski E . Activation of innate immunity is required for efficient nuclear reprogramming. Cell. 2012; 151(3):547-58. PMC: 3506423. DOI: 10.1016/j.cell.2012.09.034. View

Zitvogel L, Galluzzi L, Kepp O, Smyth M, Kroemer G . Type I interferons in anticancer immunity. Nat Rev Immunol. 2015; 15(7):405-14. DOI: 10.1038/nri3845. View

Manic G, Signore M, Sistigu A, Russo G, Corradi F, Siteni S . CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells. Gut. 2017; 67(5):903-917. PMC: 5890648. DOI: 10.1136/gutjnl-2016-312623. View

Hanzelmann S, Castelo R, Guinney J . GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013; 14:7. PMC: 3618321. DOI: 10.1186/1471-2105-14-7. View

Kroemer G, Galassi C, Zitvogel L, Galluzzi L . Immunogenic cell stress and death. Nat Immunol. 2022; 23(4):487-500. DOI: 10.1038/s41590-022-01132-2. View

10.

Meacham C, Morrison S . Tumour heterogeneity and cancer cell plasticity. Nature. 2013; 501(7467):328-37. PMC: 4521623. DOI: 10.1038/nature12624. View

11.

Sheng W, LaFleur M, Nguyen T, Chen S, Chakravarthy A, Conway J . LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade. Cell. 2018; 174(3):549-563.e19. PMC: 6063761. DOI: 10.1016/j.cell.2018.05.052. View

12.

Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot D, Adam J . Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med. 2014; 20(11):1301-9. DOI: 10.1038/nm.3708. View

13.

Topper M, Vaz M, Marrone K, Brahmer J, Baylin S . The emerging role of epigenetic therapeutics in immuno-oncology. Nat Rev Clin Oncol. 2019; 17(2):75-90. PMC: 7254932. DOI: 10.1038/s41571-019-0266-5. View

14.

Lorenzi S, Mattei F, Sistigu A, Bracci L, Spadaro F, Sanchez M . Type I IFNs control antigen retention and survival of CD8α(+) dendritic cells after uptake of tumor apoptotic cells leading to cross-priming. J Immunol. 2011; 186(9):5142-50. DOI: 10.4049/jimmunol.1004163. View

15.

Hu Y, Smyth G . ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods. 2009; 347(1-2):70-8. DOI: 10.1016/j.jim.2009.06.008. View

16.

Vacchelli E, Ma Y, Baracco E, Sistigu A, Enot D, Pietrocola F . Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science. 2015; 350(6263):972-8. DOI: 10.1126/science.aad0779. View

17.

Dawson M, Kouzarides T . Cancer epigenetics: from mechanism to therapy. Cell. 2012; 150(1):12-27. DOI: 10.1016/j.cell.2012.06.013. View

18.

Vitale I, Shema E, Loi S, Galluzzi L . Intratumoral heterogeneity in cancer progression and response to immunotherapy. Nat Med. 2021; 27(2):212-224. DOI: 10.1038/s41591-021-01233-9. View

19.

Lucarini V, Buccione C, Ziccheddu G, Peschiaroli F, Sestili P, Puglisi R . Combining Type I Interferons and 5-Aza-2'-Deoxycitidine to Improve Anti-Tumor Response against Melanoma. J Invest Dermatol. 2016; 137(1):159-169. DOI: 10.1016/j.jid.2016.08.024. View

20.

Bruno T, De Nicola F, Corleone G, Catena V, Goeman F, Pallocca M . Che-1/AATF-induced transcriptionally active chromatin promotes cell proliferation in multiple myeloma. Blood Adv. 2020; 4(22):5616-5630. PMC: 7686885. DOI: 10.1182/bloodadvances.2020002566. View